Roberts Mitani: An Alternative Strategy for Life Science Investing

At a time when bankers and investors, driven by quarter-to-quarter results, are always on the look-out for the next deal, Roberts Mitani has a different philosophy for investing in life sciences. "Our firm is built on developing long-term relationships with clients," says principal Bruce Roberts. "Building long-term relationships with clients allows us to be creative; for example, we can work on smaller transactions if that's what the client needs, because we receive warrants for our participation, and, unlike other banks, we know we'll be sticking around to witness the benefits of that kind of deal." The firm is also able to integrate both US and overseas investors.

When one first meets Bruce Roberts and Hideki Mitani, managing directors of their eponymous global private equity and financial/strategic advisory firm based in New York and Tokyo, neither strikes you as particularly contrarian in nature. Both Roberts, a thoughtful, Harvard-trained former corporate lawyer and successful businessman, and Mitani, an energetic former investment banker with 29 years of experience including stints at Goldman Sachs and Sumitomo Bank, would evidently have been quite at home in their previous corporate environments. But once you begin discussing with them the current state of life science investing, you then understand their passionate belief in the need for a change in how both traditional investment banks and private investors approach this market and why the two joined forces to create an organization designed to offer life science companies and investors an alternative approach to doing business.

At a time when bankers and investors are driven by quarter-to-quarter results and always on the look-out for the next...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.